The effectiveness of the BGC therapy will be ensured by consecutive follow-up contacts by phone or email over a period of 12 weeks.
PFÜTZNER Science & Health Institute In House global diagnostics leader
 

In Pfützner-PharmGenomics-Egypt department of in-vitro diagnostic (IVD) test performance for clinical diagnostics in the area of pharmacogenetics and individualized medicine. Our diagnostics products are based on a novel Macroarray-Technology and allow for the first time an economic comprehensive pharmacogenetic examination for clinical applications and for large amounts of genetic markers (i.e. mutations in disease-relevant genes), which can be screened simultaneously. This multiplexing technique is highly suitable to prepare a comprehensive picture of several markers in short time. Furthermore, the technology can be applied to a wide range of other bio-markers in the field of mRNA and proteins


PGx GenoChips The patented PharmGenomics GenoChip Technology (PGx GenoChip Technology) combines the advantage of a new, user-friendly and robust platform with a colorimetric detection method. This in turn allows the abdication of special and expensive laboratory equipment and together with a notebook, read-out device and the likewise in-house developed software, you receive a complete package, which is easily integrated in every laboratory.
This technology is the optimal tool for the preparation of multiplex DNA-, mRNA- and protein assays, especially in the area of personalized medicine. The following DNA Macroarrays are currently available from Pfutzner-PharmGenomics-Egypt


5-FU: Next to age, gender and environmental influences such as diet and comedication, there are genetic factors that can have a major impact on the catalytic activity of many enzymes. It is known that patients with decreased or totally absent function of the Dihydropyrimidin-Dehydrogenase (DPD) enzyme, are at a higher risk to develop severe to lethal side effects upon chemotherapy with 5-Fluorouracil (5-FU). Those are ranging between grades 3-4 according to the WHO.


CYP2D6: Tamoxifen is a selective estrogen receptor modulator, which is used for the therapy of estrogen receptor positive breast cancer. It is applied both as prevention from relapse after successful surgery and as prophylaxis in risk patients.


Liver Detoxification: The human body is continuously confronted with foreign and to some extent toxic substances. These xenobiotics include drugs, stimulants and chemicals. A great many of these foreign substances cannot be readily excreted as they are lipophilic, i.e. poorly or not at all water-soluble. Biotransformation prevents accumulation of xenobiotics by transforming lipophilic compounds into more hydrophilic ones that can be excreted from the body. Additionally biotransformational processes are involved in converting pro-drugs (inactive medication precursors) into their active forms. 


Reactive oxygen species (ROS) are damaging to all kinds of biomolecules. During biotransformation, as well as by drugs and environmental toxins, ROS can be produced inside the body. The antioxidative system is engineered to eliminate ROS and protect cells before they are damaged. Among others, cancer and neurodegenerative diseases can be the consequence of impaired ROS clearing, e.g. by dysfunctional enzymes.